21 Jul 2019 Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)
19 Jul 2019 EMA Accepts Samsung Bioepis’ MAA for SB8 Bevacizumab Biosimilar Candidate
19 Jul 2019 Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
18 Jul 2019 MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
17 Jul 2019 Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
17 Jul 2019 Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics
16 Jul 2019 Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
16 Jul 2019 Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
16 Jul 2019 Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
16 Jul 2019 FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
16 Jul 2019 SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients
13 Jul 2019 Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
10 Jul 2019 FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
09 Jul 2019 FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
08 Jul 2019 Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab
08 Jul 2019 Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471
08 Jul 2019 Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab
08 Jul 2019 Concizumab phase 2 data demonstrate its potential as a safe and efficacious subcutaneous prophylaxis treatment for all patients with haemophilia
07 Jul 2019 Positive Data from Completed Phase 1/2a study of BIVV001 Presented at ISTH 2019
05 Jul 2019 GamaMabs Pharma announces presentation of murlentamab phase 2 study results in colorectal cancer at ESMO World Congress on Gastrointestinal Cancer
04 Jul 2019 Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
04 Jul 2019 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
04 Jul 2019 BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
03 Jul 2019 GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
02 Jul 2019 Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up